Pyxis Oncology, Inc. (NASDAQ:PYXS) Position Reduced by Deutsche Bank AG

Deutsche Bank AG decreased its stake in Pyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) by 87.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 30,300 shares of the company's stock after selling 208,090 shares during the period. Deutsche Bank AG owned 0.05% of Pyxis Oncology worth $47,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Ameriprise Financial Inc. bought a new stake in shares of Pyxis Oncology in the 4th quarter worth approximately $35,000. Caption Management LLC bought a new stake in shares of Pyxis Oncology during the fourth quarter valued at approximately $35,000. Commonwealth Equity Services LLC raised its holdings in shares of Pyxis Oncology by 61.5% during the fourth quarter. Commonwealth Equity Services LLC now owns 26,250 shares of the company's stock valued at $41,000 after buying an additional 10,000 shares during the last quarter. Bank of America Corp DE raised its holdings in shares of Pyxis Oncology by 20.3% during the fourth quarter. Bank of America Corp DE now owns 53,745 shares of the company's stock valued at $84,000 after buying an additional 9,062 shares during the last quarter. Finally, Sei Investments Co. bought a new stake in shares of Pyxis Oncology during the fourth quarter valued at approximately $95,000. Institutional investors own 39.09% of the company's stock.

Analysts Set New Price Targets

PYXS has been the topic of a number of recent analyst reports. HC Wainwright reaffirmed a "buy" rating and set a $5.00 price target on shares of Pyxis Oncology in a report on Monday, May 19th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $8.00 price target on shares of Pyxis Oncology in a report on Wednesday, March 19th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $9.00.

Pyxis Oncology Stock Performance

Shares of PYXS traded up $0.11 during mid-day trading on Friday, reaching $1.35. 620,781 shares of the company's stock traded hands, compared to its average volume of 743,698. Pyxis Oncology, Inc. has a 12 month low of $0.83 and a 12 month high of $5.39. The stock has a market capitalization of $83.63 million, a P/E ratio of -1.31 and a beta of 1.18. The business's 50-day moving average price is $1.09 and its 200-day moving average price is $1.32.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last announced its earnings results on Thursday, May 15th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.06). Equities research analysts anticipate that Pyxis Oncology, Inc. will post -1.04 EPS for the current year.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.